Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

MAB3424 Anti-BrdU Antibody, clone AH4H7-1 / 131-14871

MAB3424
50 µg  
Purchase on Sigma-Aldrich

Speciální nabídky

Přehled

Replacement Information

Speciální nabídky

Tabulka spec. kláve

Species ReactivityKey ApplicationsHostFormatAntibody Type
AFC, ICC, IHCMPurifiedMonoclonal Antibody
Description
Catalogue NumberMAB3424
ReplacesMAB1467
Brand Family Chemicon®
Trade Name
  • Chemicon
DescriptionAnti-BrdU Antibody, clone AH4H7-1 / 131-14871
Alternate Names
  • BrdU
Background InformationBromodeoxyuridine (BrdU) is a thymidine analog and is specifically incor-porated into DNA during DNA synthesis. Anti-bromodeoxyuridine monoclonal antibody is used to identify cells that have incorporated BrdU. This immunological detection scheme has several advantages over the use of radioactive thymidine incorporation for identifying cells under-going replication. Labeling and detection can be performed the same day instead of waiting several days, as required for autoradiography of tritium-labeled cells, and the necessity of using multiple specimens for obtaining the optimal exposure time is eliminated. In addition, anti-bromodeoxyuridine staining with flow cytometric analysis allows multiple parameters to be evaluated simultaneously. Anti-bromodeoxyuridine monoclonal antibody has been used for identi-fying proliferating cells in blood (Campana et al., 1988), tissues (Schutte et al., 1987; Hayashi, et al., 1988), tumors (Hoshino et al., 1986; Morstyn et al., 1983), as well as for determining plasma cell labeling indices (Greipp et al., 1985).
References
Product Information
FormatPurified
HS Code3002 15 90
Control
  • After incorporation of BrdU, all DNA containing species
PresentationLiquid in 10 mM Phosphate buffer, pH 7.4 containing 150 mM NaCl and 0.1% sodium azide
Quality LevelMQ100
Applications
ApplicationUse Anti-BrdU Antibody, clone AH4H7-1 / 131-14871 (Mouse Monoclonal Antibody) validated in FC, ICC, IHC to detect Bromodeoxyuridine also known as BrdU.
Key Applications
  • Flow Cytometry
  • Immunocytochemistry
  • Immunohistochemistry
Application NotesImmunohistochemistry: (6 μg/ml)

Flow Cytometry: (0.2 μg/100 μl/10E6 cells) Optimal working dilutions must be determined by end user.

APPLICATIONS

Flow cytometry:The method below is based on that of M. Vanderlaan et al. (1986). Variations of this method exist in the literature, one consideration being the effect various fixation procedures have on the light-scattering properties of different cell populations. Procedure:

1. To label cells, pulse with 10 μM bromodeoxyuridine for 30 minutes. Harvest cells from culture.

2. Fix cells in 70% ethanol at +2-8°C for at least 30 min. Extract histones by resuspending cells in 1 mL chilled 0.1 M HCI containing 0.5% Triton X-100; incubate the suspension on ice for 10 minutes. Dilute acid with 5 mL distilled water and centrifuge at 200 x g for 10 min. Resuspend cells in 2 mL distilled water.

3. Denature cellular DNA by submerging the cell suspension into a boiling water bath for 10 min. Afterwards, quickly cool by placing the cell suspension in an ice slurry for several minutes. Wash cells in PBS that contains 0.5% Triton X-100.

4. Resuspend the cells (1-2 x 10 6 cells) in 100 μL of solution containing approximately 2 μg/mL anti-bromodeoxyuridine antibody diluted in PBS containing 0.1% BSA (0.2 μg/test). Incubate for 30 min at room temperature. Wash cells with PBS.

5. Resuspend cells in 100 μL of diluted goat anti-mouse IgG-FlTC Wash cells with PBS.

APPLICATIONS (Cont.)

Immunohistochemistry: Below is a procedure for staining cells that have been labeled with BrdU in vivo or in vitro. The procedure is based on the methods of B. Schutte et al. (1987) and D. Campana et al. (1988).

Preparation of tissue:

Inject animal with 50 mg BrdU/kg body weight. Sacrifice animal one hour later and remove organ or tissue under study. Embed tissue in OCT medium and snap-freeze by immersion into liquid nitrogen.Cut 4 mm frozen sections with a cryostat. Place sections on either albumin- or gelatin-coated slides.

Preparation of cells:

Pulse cells with 10 mM BrdU for 60 min. Cells grown on coverslips, or cytocentrifuge preparations made from cells grown in suspension, can be used for anti-bromodeoxyuridine staining according to the procedure below.

Procedure

1. Fix tissue sections or cells (on slide or coverglass) by immersing in absolute methanol for 10 minutes at +2-8°C. Air dry after removing from fixative. The slides can be stored at -20°C in a sealed box, or rehydrated to prepare for the assay procedure. To rehydrate, immerse in PBS for 3 min.

2. Denature DNA by incubating the slides in 2 N HCI for 60 min at +37°C.

3. Neutralize the acid by immersing the slides in 0.1 M borate buffer, pH 8.5. Change the buffer twice over a 10 min period.

4. Wash slides with PBS, changing the solution three times over a 10 min period.

5. Place slides in a humidified chamber (e.g., a sealed plastic box layered with wet paper towels) and cover cells with 150-300 μL of solution containing approximately 6 μg/mL anti-bromodeoxyuridine antibody diluted in PBS with 0.1% BSA. Incubate for 60 min at room temperature.

6. Wash slides with PBS, changing the solution three times over a 10 min period.

7. Apply optimal dilution of a second antibody conjugate (e.g., anti-mouse IgG-peroxidase), incubate, wash, and perform detection with a substrate that produces an insoluble product. After detection, counterstain with Harris-modified hematoxylin if desired. Slides can then be dehydrated and mounted.
Biological Information
ImmunogenBromodeoxyuridine-bovine serum albumin concentrate
CloneAH4H7-1 / 131-14871
ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
HostMouse
SpecificityBinds to bromodeoxyuridine and crossreacts with iodouridine (10%). Anti-bromodeoxyuridine does not crossreact with fluorodeoxyuridine, nor with any endogenous cellular components such as thymidine or uridine.
IsotypeIgG1
Species Reactivity
  • All
Antibody TypeMonoclonal Antibody
Purification MethodProtein A Purfied
Molecular Weightdependent upon the molecular weight of the bromodeoxyuridine incorporated protein being detected
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsMaintain for 6 months at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Packaging Information
Material Size50 µg
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Katalogové číslo GTIN
MAB3424 04053252668319

Documentation

Anti-BrdU Antibody, clone AH4H7-1 / 131-14871 MSDS

Title

Safety Data Sheet (SDS) 

Anti-BrdU Antibody, clone AH4H7-1 / 131-14871 Certificates of Analysis

TitleLot Number
Anti-Bromodeoxyuridine, clone AH4H7-1 / 131-14871 - 2420381 2420381
Anti-Bromodeoxyuridine, clone AH4H7-1 / 131-14871 - 2145042 2145042
Anti-Bromodeoxyuridine, -2519302 2519302
Anti-Bromodeoxyuridine, -2637116 2637116
Anti-Bromodeoxyuridine, -2661403 2661403
Anti-Bromodeoxyuridine, -2736634 2736634
Anti-Bromodeoxyuridine, -2802044 2802044
Anti-Bromodeoxyuridine, clone AH4H7-1 / 131-14871 - 2302155 2302155
Anti-Bromodeoxyuridine, clone AH4H7-1 / 131-14871 - 3278035 3278035
Anti-Bromodeoxyuridine, clone AH4H7-1 / 131-14871 - 3445844 3445844

References

Reference overviewApplicationPub Med ID
Hemodynamic forces regulate developmental patterning of atrial conduction.
Bressan, MC; Louie, JD; Mikawa, T
PloS one  9  e115207  2014

Zobrazit abstrakt
25503944 25503944
Inducing and characterizing liver regeneration in mice: Reliable models, essential "readouts" and critical perspectives.
Mastellos, DC; Deangelis, RA; Lambris, JD
Current protocols in mouse biology  3  141-170  2013

Zobrazit abstrakt
24416636 24416636
Higher 5-hydroxymethylcytosine identifies immortal DNA strand chromosomes in asymmetrically self-renewing distributed stem cells.
Huh, YH; Cohen, J; Sherley, JL
Proceedings of the National Academy of Sciences of the United States of America  110  16862-7  2013

Zobrazit abstrakt
24082118 24082118
Delayed hyperbaric oxygen therapy induces cell proliferation through stabilization of cAMP responsive element binding protein in the rat model of MCAo-induced ischemic brain injury.
Mu, J; Ostrowski, RP; Soejima, Y; Rolland, WB; Krafft, PR; Tang, J; Zhang, JH
Neurobiology of disease  51  133-43  2013

Zobrazit abstrakt
23146993 23146993
Periadolescent ethanol vapor exposure persistently reduces measures of hippocampal neurogenesis that are associated with behavioral outcomes in adulthood.
Ehlers, CL; Liu, W; Wills, DN; Crews, FT
Neuroscience  244  1-15  2013

Zobrazit abstrakt
23567812 23567812
Effect of rosiglitazone on capillary density and angiogenesis in adipose tissue of normoglycaemic humans in a randomised controlled trial.
O Gealekman,N Guseva,K Gurav,A Gusev,C Hartigan,M Thompson,S Malkani,S Corvera
Diabetologia  55  2011

Zobrazit abstrakt
22847059 22847059
Progressive alopecia reveals decreasing stem cell activation probability during aging of mice with epidermal deletion of DNA methyltransferase 1.
Li, J; Jiang, TX; Hughes, MW; Wu, P; Yu, J; Widelitz, RB; Fan, G; Chuong, CM
The Journal of investigative dermatology  132  2681-90  2011

Zobrazit abstrakt
22763785 22763785
Molecular mechanisms of basic fibroblast growth factor effect on healing of ulcerative colitis in rats.
Paunovic, B; Deng, X; Khomenko, T; Ahluwalia, A; Tolstanova, G; Tarnawski, A; Szabo, S; Sandor, Z
The Journal of pharmacology and experimental therapeutics  339  430-7  2010

Zobrazit abstrakt
21841041 21841041
Long-term suppression of forebrain neurogenesis and loss of neuronal progenitor cells following prolonged alcohol dependence in rats.
Hansson AC, Nixon K, Rimondini R, Damadzic R, Sommer WH, Eskay R, Crews FT, Heilig M
Int J Neuropsychopharmacol  2009

Zobrazit abstrakt
20334723 20334723
c-myc and N-myc promote active stem cell metabolism and cycling as architects of the developing brain.
Alice Wey,Paul S Knoepfler
Oncotarget  1  2009

Zobrazit abstrakt
20651942 20651942